Skip to main content

Table 3 Factors associated with sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1-infected patients

From: Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients

  Univariate analyses Multivariate analyses
Odds ratio (95%CI) P-value Odds ratio (95%CI) P-value
Age < 50 years 1.93 (1.10–3.38) 0.02 1.76 (0.71–4.37) 0.22
Female 1.26 (0.76–2.09) 0.37   
BMI 1.02 (0.95–1.10) 0.51   
Alcohol drinking 0.82 (0.46–1.46) 0.50   
Diabetes Mellitus 0.78 (0.42–1.45) 0.44   
HCV RNA (log IU/ml) 0.76 (0.55–1.07) 0.11   
ALT 0.99 (0.99–1.00) 0.46   
AST 0.99 (0.99–1.00) 0.44   
Liver fibrosis stage 0–1 3.88 (1.83–8.20) <0.001 5.00 (2.02–12.37) <0.001
CYP27B1 rs10877012 CA/AA 1.67 (0.92–3.02) 0.09 1.24 (0.47–3.29) 0.67
DHCR7 rs12785878 GT/TT 1.93 (1.05–1.96) 0.032 2.69 (1.03–7.05) 0.04
  1. AST aspartate aminotransferase, ALT alanine aminotransferase, BMI body mass index, HCV RNA hepatitis C virus RNA, 95%CI 95% confidence interval